THE MOMENT YOUR GUT INSTINCT WAS BACKED BY SCIENTIFIC RESULTS

THE DIFFERENCE OF BREAKTHROUGH MOMENTS

WITH COMPLETE SOLUTIONS FOR GROUNDBREAKING DISCOVERIES FROM A TRUSTED PARTNER.

Your next breakthrough could be closer than you imagine, especially with the right resources to help you advance your research. At BD, we are dedicated to helping you get the data you need, when, where and how you need it. Our integrated solutions in instrumentation, software and reagents are optimized to work together to bring you closer to your next breakthrough moment. And you can depend on us for world-class training, service and support to help you get the most from the results your research depends on. Discover a range of optimized solutions that open endless possibilities for your future research. Discover the new BD.

Learn how you can advance your research >
A prospective evaluation of plasma polyphenol levels and colon cancer risk

Neil Murphy 1, David Achaintre 1, Raul Zamora-Ros 2, Mazda Jenab 3, Marie-Christine Boutron-Ruault 3, Franck Carbonnel 1,4, Isabelle Savoye 1,15, Rudolf Kaaks 4, Tilman Kühn 5, Heiner Boeing 2, Krasmira Aleksandrova 6, Anne Tjønneland 3, Cecile Kyro 3, Kim Overvad 6, J. Ramón Quirós 11, Maria-Jose Sánchez 12,13, Jone M. Altzibar 13,14, José María Huerta 11,13,15, Aurelio Barricarte 13,16,17, Kay-Tee Khaw 18, Kathryn E. Bradbury 19, Aurora Perez-Cornago 19, Antonia Trichopoulou 20, Anna Karakatsani 20,21, Eleni Peppa 20, Domenico Palli 22, Sara Grioni 23, Rosario Tumino 24, Carlotta Sacerdote 25, Salvatore Panico 26, H. B(as) Bueno-de-Mesquita 27,28,29,30, Petra H. Peeters 31,32, Sara Grioni 23, Rosario Tumino 24, Carlotta Sacerdote 25, Salvatore Panico 26, H. B(as) Bueno-de-Mesquita 27,28,29,30, Petra H. Peeters 31,32, Martin Rutegård 33, Ingegerd Johansson 34, Heinz Freisling 1, Hwayoung Noh 1, Amanda J. Cross 29, Paolo Vineis 32, Kostas Tsilidis 29,35, Marc J. Gunter 1 and Augustin Scalbert 1

1 Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France
2 Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
3 CESP, INSERM U508, Univ. Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif Cedex, France
4 Université Paris Sud and Gastroenterology Unit, Hôpitaux Universitaires Paris Sud, CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France
5 Gustave Roussy, Espace Maurice Tabula, Villejuif Cedex, France
6 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
7 Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany
8 Department of Epidemiology, Nutrition, Immunity and Metabolism Start-up Lab, Potsdam-Rehbrücke, Germany
9 Danish Cancer Society Research Center, Copenhagen, Denmark
10 Department of Public Health, Aarhus University, Aarhus, Denmark
11 Public Health Directorate, Asturias, Spain
12 Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
13 CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
14 Osakidetza/Basque Health Service, Breast Cancer Screening Program, Bilbao, Spain
15 Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain

Key words: colon cancer, polyphenols, biomarkers, EPIC, nested case–control study

Disclosure of Potential Conflicts of Interest: The authors declare no potential conflicts of interest.

For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at http://epic.iarc.fr/access/index.php

This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Grant sponsors: European Commission (DG-SANCO), International Agency for Research on Cancer, Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LR Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LR Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health; Grant sponsor: Health Research Fund (FIS); Grant numbers: PI13/00661, PI13/01162; Grant sponsor: Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC; Grant number: RD06/0020; Grant sponsors: Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten; Grant sponsor: Cancer Research UK; Grant numbers: 14136, C570/A16491, C8221/A19170; Grant sponsor: Medical Research Council; Grant numbers: 1000143, MR/M012190/1; Grant sponsor: Institute of Health Carlos III and the European Social Fund (ESF); Grant number: CP15/00100

DOI: 10.1002/ijc.31563

History: Received 7 Dec 2017; Accepted 26 Mar 2018; Online 26 Apr 2018

Correspondence to: Neil Murphy, PhD, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, Cedex 08, France, E-mail: murphyn@iarc.fr and Augustin Scalbert, PhD, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, Cedex 08, France, E-mail: scalberta@iarc.fr
Polyphenols have been shown to exert biological activity in experimental models of colon cancer; however, human data linking specific polyphenols to colon cancer is limited. We assessed the relationship between pre-diagnostic plasma polyphenols and colon cancer risk in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition study. Using high pressure liquid chromatography coupled to tandem mass spectrometry, we measured concentrations of 35 polyphenols in plasma from 809 incident colon cancer cases and 809 matched controls. We used multivariable adjusted conditional logistic regression models that included established colon cancer risk factors. The false discovery rate ($q_{\text{value}}$) was computed to control for multiple comparisons. All statistical tests were two-sided. After false discovery rate correction and in continuous log2-transformed multivariable models, equol (odds ratio [OR] per log2-value, 0.86, 95% confidence interval [95% CI] 0.61–0.93; $q_{\text{value}}$ = 0.01) and homovanillic acid (OR per log2-value, 1.46, 95% CI 1.16–1.84; $q_{\text{value}}$ = 0.02) were associated with colon cancer risk. Comparing extreme fifths, equol concentrations were inversely associated with colon cancer risk (OR = 0.61, 95% CI = 0.41–0.91, $p_{\text{trend}}$ = 0.003), while homovanillic acid concentrations were positively associated with colon cancer development (OR = 1.72, 95% CI = 1.17–2.53, $p_{\text{trend}}$ < 0.0001). No heterogeneity for these associations was observed by sex and across other colon cancer risk factors. The remaining polyphenols were not associated with colon cancer risk. Higher equol concentrations were associated with lower risk, and higher homovanillic acid concentrations were associated with greater risk of colon cancer. These findings support a potential role for specific polyphenols in colon tumorigenesis.

What’s new?
Polyphenols are antioxidants abundant in food, and some polyphenols have demonstrated an anti-cancer effect. Here, the authors looked for an association between polyphenols and colon cancer risk by conducting a nested case–control analysis within the EPIC cohort. Rather than employing questionnaires that rely on participant memories of their diet, this study directly measured 35 polyphenols in plasma samples and compared them with colon cancer risk. Only 2 chemicals showed any association. Concentrations of equol, which is metabolized from soy foods, were inversely associated with colon cancer risk. Higher levels of homovanillic acid, on the other hand, were associated with increased risk.

Polyphenols are plant-based bioactive compounds characterized by the presence of phenolic group(s) in their structure. Polyphenols are abundant in the human diet and dietary sources such as fruits, vegetables, nuts, legumes, whole-grain cereals, cocoa, soya beans, tea, coffee and wine.1,2 Over 500 different polyphenols have been identified from dietary sources and can be broadly divided into four common classes: phenolic acids, flavonoids, lignans and stilbenes.1 Polyphenols are the most abundant antioxidants in the human diet,3 and are postulated to confer anti-inflammatory and estrogenic effects (e.g., isoflavonoids).4,5 Once ingested, they can be metabolized by the intestinal microbiota into low-
molecular weight phenolic acids and into various conjugated forms (e.g., glucuronides) in human tissues.\textsuperscript{1,6}

Experimental evidence supports a chemo-preventive role for certain polyphenols against colon cancer development. Phenolic acids, such as caffeic acid and ferulic acid, have been shown to have anti-proliferative effects on colon cancer in $\textit{in vitro}$ and $\textit{in vivo}$ investigations.\textsuperscript{7–9} Flavonoids have been demonstrated to induce apoptosis and inhibit colon cancer cell line growth.\textsuperscript{10–12} Nevertheless, prospective epidemiological studies of colon cancer which measured polyphenol intakes \textit{via} dietary questionnaires have reported largely null results. In the Nurses’ Health Study, Health Professionals Follow-up Study, and the European Prospective Investigation into Cancer and Nutrition (EPIC) study, dietary intakes of flavonoids and its sub-classes were unrelated to colon cancer risk.\textsuperscript{13–15} Such analyses are reliant on participant’s self-reporting previous dietary intakes accurately and the availability of reliable data from databases on the polyphenol content of foods. A more objective, and potentially more accurate approach to assess how polyphenols are associated with colon cancer risk, is to directly measure levels of polyphenols directly in bio-specimens. Previous studies, which have undertaken such analyses have been of relatively small size, focused on small selections of polyphenols, and have produced inconclusive results.\textsuperscript{16–18}

To provide more conclusive evidence on the association of polyphenol levels and colon cancer we conducted a nested case–control analysis within the EPIC cohort, in which we measured 35 polyphenols in prospectively collected plasma samples using a recently developed method based on mass spectrometry and studied their associations with colon cancer risk.

Methods

Study population and collection of blood samples and data

EPIC is a multicenter prospective cohort of 521,330 participants, mostly aged \(\geq 35\), who were recruited in 1992–2000, predominantly from the general population of 10 European countries.\textsuperscript{19,20} Additional detail on the study population is provided in the Supporting Information Methods. Blood samples were collected at recruitment according to standardized procedures\textsuperscript{19,20} and stored at the International Agency for Research on Cancer (\(-196\,^\circ\text{C}, \text{liquid-nitrogen}\)) for all countries except Denmark (\(-150\,^\circ\text{C}, \text{nitrogen-vapor}\)) and Sweden (\(-80\,^\circ\text{C}, \text{freezers}\)). Participants completed standardized lifestyle and personal history questionnaires at recruitment, and most participants also had anthropometric measurements and blood samples taken at recruitment before disease onset or diagnosis. Diet over the previous 12-months was assessed at recruitment using validated country/center-specific dietary questionnaires.\textsuperscript{19,20} All participants provided written informed consent. Ethical approval for the EPIC study was obtained from the review boards of the International Agency for Research on Cancer (IARC) and local participating centers.

Follow-up for cancer incidence

Cancer incidence was determined through record linkage with regional cancer registries (Denmark, Italy, the Netherlands, Spain, Sweden, United Kingdom) or \textit{via} a combination of methods, including the use of health insurance records, contacts with cancer and pathology registries and active follow-up through participants and their next of kin (France, Germany, Greece). Colon cancer cases were defined using the tenth revision of the International Classification of Diseases (ICD-10) and the second revision of the International Classification of Diseases for Oncology (ICDO-2). Colon cancers include those within the proximal (C18.0–18.5), distal (C18.6–C18.7), overlapping (C18.8) and unspecified (C18.9) regions.

Selection of cases and controls

Controls were selected from the all participants who were alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the cases, using incidence density sampling, and with controls matched to cases by age, sex, study center, follow-up time since blood collection, time of day at blood collection, fasting status, menopausal status and phase of menstrual cycle at blood collection. The current study included 809 incident colon cancer cases and 809 matched controls.

Laboratory methods

Plasma polyphenol measurements were undertaken at IARC (France) using a differential isotope labeling method and mass spectrometry (Achaintre \textit{et al.} under review). The 35 polyphenols measured are listed in Table 2. Citrated plasma samples were first treated with a $\beta$-glucuronidase/sulfatase enzyme mixture containing ascorbic acid and the resulting polyphenol aglycones were extracted twice with ethyl acetate. Quenching was applied by evaporation under vacuum followed by reconstitution with water/acetonitrile. Quantitative dansylation of phenolic hydroxyl groups was carried out with either $^{13}$C-labeled dansyl chloride (samples) or non-labeled dansyl chloride (well-characterized reference pooled sample). Each $^{13}$C-dansylated sample was mixed with the $^{12}$C-dansylated reference sample, and the relative concentrations in samples over the reference sample were determined in batches of 50 samples by ultra-high pressure liquid chromatography coupled to tandem mass spectrometry \textit{via} an electrospray interface. Limits of quantification for the polyphenols varied between 0.11 nmol/L for apigenin and 44.4 nmol/L for quercetin. Intra-batch coefficients of variation varied between 2.3% and 9%. Inter-batch coefficients of variations were <20% for all except four polyphenols (quercetin, gallic acid, hydroxytyrosol and enterodiol). Spiking experiments showed good accuracy for 29 polyphenols (72%–122% recovery) and satisfactory for the others (43%–62%). Dilution experiments also showed good recovery (90%–120%) for 30 of the 35 compounds tested.
Statistical analysis

Spearman’s rank correlation coefficients were calculated to assess the correlations between plasma concentrations of polyphenols and dietary variables among control participants. Multivariable conditional logistic regression, stratified by case–control set, was used to compute odds ratios (ORs) and 95% confidence intervals (95% CI) for the associations between log_{2}-transformed plasma polyphenol concentrations and colon cancer risk. The basic model was conditioned on the matching factors only, while the multivariable model included additional adjustment for body mass index (BMI), height, physical activity, smoking status, prevalent diabetes, education level, alcohol consumption, ever use of postmenopausal hormone therapy (HT) and dietary intakes of total energy, red and processed meats and fiber. False discovery rate (FDR; q_{value}) correction was performed using the Benjamini–Hochberg method. Additional analyses were then conducted for polyphenols which were associated with colon cancer after correction for multiple comparisons (q_{value} < 0.05). For these analyses, participants were divided into fifths based on polyphenol concentrations in the control group, and multivariable conditional logistic regression models were undertaken. Statistical tests for trend (p_{trend}) for a given analyte were calculated using the ordinal quartile entered into the models as a continuous variable. Possible nonlinear effects were modeled using restricted cubic spline models. Sub-group analyses were conducted by anatomical site (proximal colon and distal colon), sex, BMI, ever use of HT, age at recruitment and dairy product consumption (above and below median based on distribution of the control group), and formally tested for heterogeneity using χ² tests. To assess whether preclinical disease may have influenced the results, cases diagnosed within the first 4-years were excluded. Statistical tests used in the analysis were all two-sided.

Results

Descriptive data analysis

Compared with the control group participants, colon cancer cases had a higher BMI and homovanillic acid concentrations, and lower equol concentrations (Tables 1 and 2). Weak correlations were observed between concentrations of the 35 plasma polyphenols and dietary intakes, except for tea ((+)-epigallocatechin, r = 0.64; gallic acid, r = 0.51) and coffee (ferulic acid, r = 0.48; caffeic acid, r = 0.46) (Fig. 1). The strongest correlations (all p < 0.0001) between polyphenol concentrations were found for 3,5-dihydroxybenzoic acid and 3,5-dihydroxyphenylpropionic acid (r = 0.90); genistein and daidzein (r = 0.81); hesperetin and naringenin (r = 0.76) and quercetin and kaempferol (r = 0.71). Median (5th–95th percentile) concentrations of polyphenols among controls by country are shown in Supporting Information Table S1.

Polypheon concentrations and risk of colon cancer

Of the 35 polyphenols included in this analysis, in the multivariable models after FDR correction (q_{value}<0.05), equol and homovanillic acid were significantly associated with colon cancer risk. In continuous log_{2}-transformed multivariable models, equol was inversely (OR per log_{2}-value, 0.86, 95% CI 0.79–0.93; q_{value}=0.01; OR comparing extreme fifths] = 0.61, 95% CI = 0.41–0.91, p_{trend} = 0.003; Table 4) and

Table 1. Baseline characteristics of colon cancer cases and controls

| Baseline characteristic | Cases       | Controls    |
|-------------------------|-------------|-------------|
| Colon cancer cases (n)  | 809         | 809         |
| Men (n)                 | 323 (39.9)  | 323 (39.9)  |
| Women (n)               | 486 (60.1)  | 486 (60.1)  |
| Age at blood collection (years) | 56.8 (7.5) | 56.8 (7.4) |
| Years of follow-up¹     | 6.6 (3.7)   | -           |
| Anthropometrics¹         |             |             |
| Body mass index (kg/m²) | 26.9 (4.4)  | 26.3 (3.8)  |
| Height (cm)             | 166.4 (9.4) | 165.5 (9.5) |
| Smoking status²         |             |             |
| Never                   | 378 (46.7)  | 404 (49.9)  |
| Former                  | 242 (29.9)  | 226 (27.9)  |
| Current                 | 180 (22.3)  | 175 (21.6)  |
| Physical activity²      |             |             |
| Inactive                | 228 (28.2)  | 212 (26.2)  |
| Moderately inactive     | 295 (36.5)  | 275 (34.0)  |
| Moderately active       | 159 (19.7)  | 160 (19.8)  |
| Active                  | 125 (15.5)  | 159 (19.7)  |
| Education level²        |             |             |
| None/primary school     | 371 (46.2)  | 384 (47.7)  |
| completed               |             |             |
| Technical/professional/ secondary school | 304 (37.9) | 292 (36.3) |
| Longer education (including university degree) | 122 (15.2) | 122 (15.2) |
| Ever menopausal hormone therapy use² |           |             |
| No                      | 330 (42.4)  | 346 (44.1)  |
| Yes                     | 126 (16.2)  | 115 (14.7)  |
| Prevalent diabetes⁴     |             |             |
| No                      | 739 (95.1)  | 740 (95.2)  |
| Yes                     | 32 (4.1)    | 32 (4.1)    |
| Dietary intakes¹         |             |             |
| Alcohol consumption (g/day) | 13.8 (19.2) | 12.9 (17.4) |
| Total energy (kcal/day) | 2111.9 (751.0) | 2101.5 (639.9) |
| Red and processed meat (g/day) | 78.9 (69.1) | 78.8 (48.4) |
| Fiber (g/day)            | 22.6 (7.9)  | 23.1 (8.0)  |

¹Values are mean (standard deviation). ²Values are n (%) with participants with any missing/unknown values for baseline characteristics excluded.
Table 2. Median (5th–95th percentile) concentrations of plasma polyphenols (nmol/L) among colon cancer cases and controls

| Polyphenol class/subclass                                      | Cases          | Controls       | $p$ for difference |
|--------------------------------------------------------------|----------------|----------------|--------------------|
| **Phenolic acids/Hydroxybenzoic acids (nmol/L)**              |                |                |                    |
| 4-Hydroxybenzoic acid                                        | 202.0          | 201.0          | 0.56               |
| 3-Hydroxybenzoic acid                                        | 19.1           | 19.5           | 0.49               |
| Protocatechuic acid                                          | 155.0          | 155.0          | 0.44               |
| Gallic acid                                                  | 38.0           | 37.0           | 0.62               |
| Vanillic acid                                                | 178.0          | 176.0          | 0.60               |
| 3,5-Dihydroxybenzoic acid                                    | 28.6           | 29.0           | 0.97               |
| Gallic acid ethyl ester                                      | 1.1            | 1.1            | 0.41               |
| **Phenolic acids/Hydroxyphenylacetic acids (nmol/L)**         |                |                |                    |
| 4-Hydroxyphenylacetic acid                                   | 324.0          | 315.0          | 0.18               |
| 3-Hydroxyphenylacetic acid                                   | 58.4           | 55.3           | 0.95               |
| 3,4-Dihydroxyphenylacetic acid                               | 40.8           | 40.0           | 0.40               |
| Homovanillic acid                                            | 88.8           | 84.0           | 0.007              |
| **Phenolic acids/Hydroxyphenylpropanoic acids (nmol/L)**      |                |                |                    |
| 3,4-Dihydroxyphenylpropanoic acid                            | 193.5          | 195.0          | 0.51               |
| 3,5-Dihydroxyphenylpropanoic acid                            | 41.2           | 39.7           | 0.78               |
| **Phenolic acids/Hydroxcinnamic acids (nmol/L)**              |                |                |                    |
| $p$-Coumaric acid                                            | 17.9           | 17.7           | 0.26               |
| $m$-Coumaric acid                                            | 9.7            | 10.6           | 0.07               |
| Caffeic acid                                                 | 430.0          | 427.0          | 0.93               |
| Ferulic acid                                                 | 92.0           | 93.0           | 0.90               |
| **Flavonoids/Flavonols (nmol/L)**                            |                |                |                    |
| Kaempferol                                                   | 93.0           | 92.0           | 0.58               |
| Quercetin                                                    | 349.0          | 342.0          | 0.29               |
| **Flavonoids/Flavanols (nmol/L)**                            |                |                |                    |
| (+)-Catechin                                                 | 19.4           | 18.1           | 0.10               |
| (−)-Epicatechin                                              | 17.7           | 17.0           | 0.30               |
| (+)-Gallocatechin                                            | 11.1           | 11.1           | 0.89               |
| (−)-Epigallocatechin                                         | 11.1           | 11.1           | 0.97               |
| **Flavonoids/Flavones (nmol/L)**                             |                |                |                    |
| Apigenin                                                     | 14.7           | 14.7           | 0.51               |
| **Flavonoids/Flavanones (nmol/L)**                           |                |                |                    |
| Naringenin                                                   | 3.8            | 4.0            | 0.23               |
| Hesperetin                                                   | 2.0            | 2.3            | 0.32               |
| **Flavonoids/Isoflavonoids (nmol/L)**                        |                |                |                    |
| Daidzein                                                     | 12.8           | 12.1           | 0.76               |
| Genistein                                                    | 4.9            | 4.9            | 0.36               |
| Equol                                                        | 0.37           | 0.42           | 0.002              |
| **Flavonoids/Dihydrochalcones (nmol/L)**                     |                |                |                    |
| Phloretin                                                    | 1.1            | 1.1            | 0.73               |
| **Stilbenes (nmol/L)**                                       |                |                |                    |
| Resveratrol                                                  | 2.6            | 2.6            | 0.98               |
| **Tyrosols (nmol/L)**                                        |                |                |                    |
| Tyrosol                                                      | 3.0            | 2.9            | 0.57               |
| Hydroxytyrosol                                               | 28.1           | 27.3           | 0.47               |
homovanillic acid was positively (OR per log2-value, 1.46, 95% CI 1.16–1.84; \( q_{\text{value}} \) = 0.02; (OR[comparing extreme fifths] = 1.72, 95% CI = 1.17–2.53, \( P_{\text{trend}} < 0.0001 \)) associated with colon cancer risk (Table 3). The remaining 33 polyphenols were not associated with colon cancer risk (Table 3).
Since equol is produced by intestinal bacteria by metabolic transformation of daidzein, an isoflavone present within soya food products, the models were adjusted for daidzein and soya; the risk estimates remained unchanged after these additional adjustments (OR per log2-value with adjustment for daidzein, 0.84, 95% CI = 0.76–0.92; OR per log2-value with adjustment for soya, 0.86, 95% CI = 0.79–0.93) (Table 4). The inverse relationship was also insensitive to additional adjustment for dietary intakes of dairy products and milk, which are known dietary sources of pre-formed equol.

Table 3. Risk of colon cancer for log2-transformed polyphenol concentrations (sorted by multivariable model false discovery rate [FDR] q values)

| Basic model | Multivariable model |
|-------------|---------------------|
| OR per log2-value | 95% CI | FDR (q value) | OR per log2-value | 95% CI | FDR (q value) |
| Equol | 0.88 | 0.82–0.95 | 0.0010 | 0.03 | 0.86 | 0.79–0.93 | 0.0003 | 0.01 |
| Homovanillic acid | 1.37 | 1.12–1.68 | 0.0020 | 0.03 | 1.46 | 1.16–1.84 | 0.0012 | 0.02 |
| m-Coumaric acid | 0.94 | 0.88–1.00 | 0.0068 | 0.53 | 0.94 | 0.88–1.01 | 0.0944 | 0.63 |
| Quercetin | 1.49 | 0.96–2.30 | 0.0751 | 0.53 | 1.49 | 0.91–2.43 | 0.1148 | 0.63 |
| 3,5-Dihydroxyphenylpropionic acid | 1.02 | 0.92–1.13 | 0.7488 | 0.97 | 1.09 | 0.96–1.24 | 0.1604 | 0.63 |
| p-Coumaric acid | 1.17 | 0.93–1.47 | 0.1787 | 0.73 | 1.18 | 0.92–1.52 | 0.1830 | 0.63 |
| Naringenin | 0.96 | 0.90–1.02 | 0.1946 | 0.73 | 0.95 | 0.89–1.02 | 0.1876 | 0.63 |
| Gallic acid | 1.09 | 0.86–1.37 | 0.4750 | 0.73 | 1.20 | 0.91–1.57 | 0.1897 | 0.63 |
| (+)-Catechin | 1.10 | 0.99–1.22 | 0.0655 | 0.53 | 1.08 | 0.96–1.21 | 0.1944 | 0.63 |
| 4-Hydroxyphenylacetic acid | 1.15 | 0.96–1.37 | 0.1190 | 0.69 | 1.14 | 0.94–1.38 | 0.1966 | 0.63 |
| (+)-Epicatechin | 1.06 | 0.97–1.17 | 0.1987 | 0.73 | 1.07 | 0.96–1.19 | 0.2011 | 0.63 |
| 3,5-Dihydroxybenzoic acid | 1.00 | 0.92–1.10 | 0.9396 | 0.99 | 1.07 | 0.96–1.19 | 0.2467 | 0.63 |
| Apigenin | 1.22 | 0.77–1.94 | 0.4012 | 0.73 | 1.34 | 0.81–2.21 | 0.2545 | 0.63 |
| Protocatechuic acid | 1.46 | 0.76–2.81 | 0.2512 | 0.73 | 1.53 | 0.73–3.21 | 0.2604 | 0.63 |
| Phloretin | 1.02 | 0.92–1.13 | 0.6793 | 0.95 | 1.07 | 0.95–1.20 | 0.2714 | 0.63 |
| Hesperetin | 0.98 | 0.94–1.02 | 0.2639 | 0.73 | 0.97 | 0.93–1.02 | 0.2889 | 0.63 |
| 3,4-Dihydroxyphenylacetic acid | 1.15 | 0.89–1.48 | 0.2752 | 0.73 | 1.16 | 0.87–1.55 | 0.3068 | 0.63 |
| 3-Hydroxyphenylacetic acid | 1.00 | 0.95–1.06 | 0.9461 | 0.99 | 1.03 | 0.97–1.10 | 0.3432 | 0.67 |
| Kaempferol | 1.18 | 0.79–1.78 | 0.4215 | 0.73 | 1.24 | 0.77–2.01 | 0.3718 | 0.68 |
| 4-Hydroxybenzoic acid | 1.12 | 0.83–1.51 | 0.4768 | 0.73 | 1.16 | 0.82–1.63 | 0.3984 | 0.70 |
| Resveratrol | 1.00 | 0.91–1.10 | 0.9795 | 0.99 | 0.96 | 0.86–1.07 | 0.4173 | 0.70 |
| Vanillic acid | 1.11 | 0.87–1.42 | 0.3897 | 0.73 | 1.11 | 0.85–1.45 | 0.4555 | 0.72 |
| Genistein | 0.97 | 0.91–1.03 | 0.3203 | 0.73 | 0.98 | 0.91–1.05 | 0.5092 | 0.76 |
| Caffeic acid | 0.97 | 0.61–1.52 | 0.8854 | 0.99 | 1.19 | 0.70–2.00 | 0.5218 | 0.76 |
| Daidzein | 0.99 | 0.93–1.06 | 0.7577 | 0.97 | 0.98 | 0.91–1.05 | 0.5729 | 0.76 |
| Hydroxytyrosol | 1.09 | 0.88–1.34 | 0.4393 | 0.73 | 1.07 | 0.85–1.35 | 0.5759 | 0.76 |
| Gallic acid ethyl ester | 1.06 | 0.95–1.18 | 0.3226 | 0.73 | 1.04 | 0.91–1.18 | 0.5831 | 0.76 |
| Enterolactone | 0.98 | 0.92–1.04 | 0.4450 | 0.73 | 0.99 | 0.93–1.06 | 0.7286 | 0.90 |
| 3,4-Dihydroxyphenylpropionic acid | 0.89 | 0.68–1.16 | 0.3749 | 0.73 | 0.95 | 0.70–1.29 | 0.7481 | 0.76 |
| (+)-Epigallocatechin | 1.00 | 0.84–1.19 | 0.9845 | 0.99 | 1.03 | 0.84–1.26 | 0.8023 | 0.92 |
| Tyrosol | 1.05 | 0.92–1.19 | 0.4714 | 0.73 | 1.02 | 0.88–1.17 | 0.8133 | 0.92 |
| 3-Hydroxybenzoic acid | 0.97 | 0.87–1.08 | 0.5863 | 0.85 | 0.99 | 0.88–1.12 | 0.9111 | 0.97 |
| Ferulic acid | 0.98 | 0.84–1.14 | 0.7794 | 0.97 | 1.01 | 0.85–1.19 | 0.9211 | 0.97 |
| (+)-Gallocatechin | 0.97 | 0.69–1.37 | 0.8685 | 0.99 | 1.01 | 0.66–1.54 | 0.9557 | 0.97 |
| Enterodiol | 1.00 | 0.94–1.07 | 0.9856 | 0.99 | 1.00 | 0.93–1.07 | 0.9711 | 0.97 |

Sorted by false discovery rate (FDR) q values. OR per log2-value (95% CI)—therefore the ORs correspond to a doubling in polyphenol level. Basic model was conditioned on matching factors only. Multivariable model was conditioned on matching factors, with additional adjustment for body mass index, height, physical activity, smoking status, education level, alcohol consumption, prevalent diabetes, ever use of menopausal hormone therapy, and dietary intakes of total energy, red and processed meats and fiber.
Table 4. Risk of colon cancer for fifths of equol and homovanillic acid after further adjustment for other dietary exposures and polyphenol concentrations

|                     | 1        | 2  | 3  | 4  | 5  | \(P_{\text{trend}}\) | OR per log\(_2\)-value |
|---------------------|----------|----|----|----|----|------------------------|--------------------------|
| **Equol (nmol/L)**  |          |    |    |    |    |                        |                          |
| Basic               | 1.00     | 0.77 (0.55–1.07) | 0.75 (0.54–1.05) | 0.62 (0.44–0.87) | 0.70 (0.49–1.00) | 0.017 | 0.88 (0.82–0.95) |
| Multivariable       | 1.00     | 0.69 (0.47–1.00) | 0.66 (0.45–0.95) | 0.50 (0.34–0.74) | 0.61 (0.41–0.91) | 0.003 | 0.86 (0.79–0.93) |
| Plus dairy consumption | 1.00 | 0.71 (0.48–1.03) | 0.67 (0.46–0.98) | 0.51 (0.35–0.76) | 0.62 (0.42–0.93) | 0.005 | 0.86 (0.79–0.93) |
| Plus milk consumption | 1.00 | 0.69 (0.47–1.02) | 0.68 (0.47–0.99) | 0.53 (0.36–0.78) | 0.63 (0.42–0.95) | 0.007 | 0.86 (0.79–0.94) |
| Plus dietary calcium intake | 1.00 | 0.71 (0.49–1.04) | 0.69 (0.47–1.00) | 0.52 (0.35–0.77) | 0.64 (0.42–0.96) | 0.007 | 0.86 (0.79–0.94) |
| Plus soya product consumption | 1.00 | 0.68 (0.46–0.99) | 0.64 (0.44–0.93) | 0.50 (0.34–0.74) | 0.61 (0.41–0.91) | 0.003 | 0.86 (0.79–0.93) |
| Plus daidzein concentration | 1.00 | 0.61 (0.42–0.91) | 0.62 (0.42–0.92) | 0.48 (0.32–0.72) | 0.54 (0.35–0.84) | 0.002 | 0.84 (0.76–0.92) |
| Plus genistein concentration | 1.00 | 0.68 (0.46–0.99) | 0.66 (0.45–0.95) | 0.51 (0.35–0.76) | 0.60 (0.40–0.91) | 0.004 | 0.86 (0.79–0.94) |
| Plus daidzein and genistein concentration | 1.00 | 0.61 (0.41–0.91) | 0.62 (0.42–0.92) | 0.49 (0.32–0.74) | 0.54 (0.35–0.84) | 0.002 | 0.84 (0.76–0.92) |

| **Homovanillic acid (nmol/L)** | <65 | 65 to <78 | 78 to <91 | 91 to <118 | \(\geq 118\) | \(P_{\text{trend}}\) | OR per log\(_2\)-value |
|------------------------------|-----|-----------|------------|-------------|----------------|------------------------|--------------------------|
| Basic                        | 1.00 | 0.97 (0.70–1.36) | 1.05 (0.76–1.45) | 1.57 (1.14–2.16) | 1.54 (1.09–2.16) | <0.0001 | 1.37 (1.12–1.68) |
| Multivariable                | 1.00 | 0.97 (0.67–1.42) | 1.06 (0.73–1.52) | 1.77 (1.23–2.53) | 1.72 (1.17–2.53) | <0.0001 | 1.46 (1.16–1.84) |
| Plus 3,4-Dihydroxyphenylacetic acid concentration | 1.00 | 0.93 (0.63–1.38) | 1.06 (0.72–1.56) | 1.71 (1.16–2.51) | 1.59 (1.02–2.47) | 0.002 | 1.50 (1.12–1.99) |

Values are ORs for fifths of equol and homovanillic acid, and OR per log\(_2\) value (95% CI). Multivariable model was conditioned on matching factors, with additional adjustment for body mass index, height, physical activity, smoking status, education level, alcohol consumption, prevalent diabetes, ever use of menopausal hormone therapy and dietary intakes of total energy, red and processed meats and fiber.
A non-linear relationship was observed between equol concentrations and colon cancer risk \( (p_{\text{non-linear}} = 0.02) \), with the risk plateauing at an OR of 0.60 at plasma concentrations of 0.6 nmol/L and above (Fig. 2a). Similar strength inverse associations between equol and colon cancer were observed for women and men \( (p_{\text{heterogeneity}} = 0.54) \) (Supporting Information Table S2), and for tumors located in the proximal and distal colon \( (p_{\text{heterogeneity}} = 0.17) \) (Supporting Information Table S3). A similar association was observed for equol when colon cancer cases which occurred within the first 4-years of follow-up were excluded (OR per log2-value, 0.89, 95% CI = 0.81–0.97). Heterogeneity for the equol and colon cancer risk relationship was found by BMI \( (p_{\text{heterogeneity}} = 0.003) \), with an inverse association only apparent for the BMI < 25 kg/m².
group (OR per log₂-value, 0.81, 95% CI = 0.63–1.04), and not for the BMI ≥ 25 kg/m² group (OR per log₂-value, 0.97, 95% CI = 0.85–1.10) (data not shown). No heterogeneity was observed for the relationships between equol and colon cancer risk across strata of ever HT use ($p_{\text{heterogeneity}} = 0.28$), age at recruitment ($p_{\text{heterogeneity}} = 0.84$) and dairy consumption ($p_{\text{heterogeneity}} = 0.97$) (data not shown).

The magnitude of this positive homovanillic acid relationship was unchanged after additional statistical adjustment for concentrations of 3,4-dihydroxyphenylacetic acid, from which homovanillic acid is predominantly formed (via O-methylation) (Table 4). In the restricted cubic spline model, no evidence of non-linearity for the relationship between homovanillic acid and colon cancer was observed ($p_{\text{non-linear}} = 0.18$) (Fig. 2b). The positive relationship for homovanillic acid was similar for women and men ($p_{\text{heterogeneity}} = 0.87$) (Supporting Information Table S2), and for tumors located in the proximal and distal colon ($p_{\text{heterogeneity}} = 0.66$) (Supporting Information Table S3). A similar positive relationship was observed for homovanillic acid when colon cancer cases which occurred within the first 4-years of follow-up were excluded (OR per log₂-value, 1.39, 95% CI = 1.06–1.82). No heterogeneity was observed for the relationships between homovanillic acid and colon cancer risk strata of BMI ($p_{\text{heterogeneity}} = 0.34$) and age at recruitment ($p_{\text{heterogeneity}} = 0.25$) (data not shown).

**Discussion**

In this large-scale study that assessed polyphenols in prediagnostic plasma samples, circulating concentrations of equol were inversely, and homovanillic acid were positively, associated with colon cancer risk, even after control for established colon cancer risk factors and statistical correction for multiple comparisons. We did not observe any relationships between the other measured polyphenols and colon cancer risk.

To our knowledge, this study is the first to report an inverse relationship between equol concentrations and colon cancer risk. Equol is produced by intestinal bacteria through the metabolic conversion of daidzein, an isoflavone present within soya food products. In Western populations, circulating equol levels are relatively low due to minimal consumption of soya food products, and only ~25%–30% of the adult population are classified as “equol producers,” i.e., harboring the colonic bacteria required for the conversion of daidzein into equol. Dairy products can also be a direct source of pre-formed equol as cows fed soybean products in their feed are capable of producing equol, which is then secreted into milk, in agreement with weak correlations ($r = 0.33$) observed between urinary equol concentrations and the consumption of dairy products reported in dietary 24-hr recalls in a subset of EPIC participants. The lower risk of colon cancer we observed with high equol concentrations is consistent with an analysis of dietary equol intake and colorectal cancer in the EPIC-Norfolk cohort, but inconsistent with an analysis of circulating equol levels and colorectal cancer (221 cases) in the same study (OR per log₂ equol levels, 1.04, 95% CI = 0.99–1.09). This discrepancy may have been a consequence of the lower equol concentrations in the EPIC-Norfolk population (median = 0.04 nmol/L) compared to concentrations across all EPIC countries (median = 0.42 nmol/L). Nonetheless, compared to Asian populations, where soya consumption is much greater and ~50%–60% of the adult population are classified as “equol producers,” equol levels in our study were low. In a Japanese study, which reported an inverse relationship between equol concentrations and prostate cancer risk, a median equol level of 19.4 nmol/L was recorded. However, despite lower concentrations of equol in our European study, we nevertheless observed an inverse association with colon cancer risk.

Equol is a phytoestrogen, and in some studies higher concentrations in blood or urine have been associated with lower risks of certain reproductive system cancers such as prostate cancer and breast cancer. Equol shares structural similarity with mammalian estrogens and can similarly bind to estrogen receptors, in particular estrogen receptor-β (ERβ). Several lines of evidence support the role of estrogens potentially being beneficial against the development of colon cancer. First, experimental data have shown that expression of ERβ results in the inhibition of proliferation and G1 phase cell-cycle arrest in colon cancer cells, and in xenograft mouse studies ERβ inhibits cMyc expression and tumor growth. Second, expression of ERβ is low in human colon cancer cells and is inversely associated with stage of colon cancer, suggesting a possible role in disease progression. Third, lower incidence of colorectal cancer has been observed among postmenopausal HT users when compared with non-users. Finally, endogenous circulating estrogens have recently been associated with reduced risk of colon cancer in a case-control study nested within the Women’s Health Initiative study.

It is also possible that our observed inverse relationship between equol and colon cancer, rather than being a consequence of any phytoestrogenic effects of equol, is instead a marker of a particular community of intestinal microbiota which may be protective against the development of colon cancer. Evidence suggests that a consortium of intestinal bacteria produce equol from the metabolism of daidzein. Strains of intestinal bacteria which have been shown to convert daidzein into equol in experimental models include, amongst others, Enterococcus faecium EPI1, Finegoldia magna EPI3, Lactobacillus mucosae EPI2 and an unknown strain of Veillonella sp. Evidence also suggests that being an “equol producer” may also be associated with a lowering of circulating insulin-like growth factor-1 levels, which have been positively associated with colorectal cancer risk. Overall, the inverse relationship between equol and colon cancer observed in the current study while supported by plausible biological mechanisms requires validation by additional prospective studies.
To our knowledge, this was the first study to observe that higher homovanillic acid levels were associated with greater colon cancer risk. This relationship was consistent by sex, follow-up time and across strata of other colon cancer risk factors. Homovanillic acid is formed from the O-methylation of 3,4-dihydroxyphenylacetic acid, which is sourced from colonic microbiota metabolism of other polyphenols, such as quercetin, or from dopamine metabolism. In our study, homovanillic acid and 3,4-dihydroxyphenylacetic acid were moderately correlated ($r = 0.59$), and adjustment of the multivariable model for 3,4-dihydroxyphenylacetic acid levels did not alter the homovanillic acid—colon cancer association. Experimental data on the effects of homovanillic acid on colon cancer development are lacking but it is possible that homovanillic acid is a marker of dopamine-related metabolism. Dopamine receptors have been identified throughout the gastrointestinal tract, and human colon cancer tissue has been shown to have 3- to 10-fold lower concentrations of dopamine than normal tissue. In addition, experimental evidence suggests that dopamine regulates tumor angiogenesis and inhibits the growth of colon cancer cell lines in preclinical models. Epidemiological investigations of pre-diagnostic dopamine levels and colon cancer risk have not been undertaken. Further, it is not known how plasma concentrations of homovanillic acid and dopamine are correlated in healthy individuals and colon cancer patients. Additional prospective studies are required to corroborate the positive relationship we observed between homovanillic acid and colon cancer. Such investigations should also measure circulating dopamine levels to better understand how the degradation of dopamine and its by-products relate to colon cancer development.

Strengths of this study include the application of a newly developed analytical method able to simultaneously quantify pre-diagnostic concentrations of 35 polyphenols spanning all major classes found in the diet. The direct measurement of plasma concentrations of polyphenols captures all their possible sources or precursors and circumvents potential biases inherent to questionnaire-based data acquisition. Additional strengths of our study include the large sample size, the diverse lifestyles of participants from nine European countries which have been well characterized and allowed us to control for other risk factors which may confound the polyphenols and colon cancer relationships. Nevertheless, as is the case in all observational epidemiological studies, we cannot rule out the possibility that residual confounding influenced the relationships we observed. A limitation is that most polyphenols show a relatively short half-life in plasma, resulting in moderate-to-high intra-individual variability depending on the compounds, unless their sources are regularly consumed. Single plasma samples from baseline were used to assess the observed relationships, meaning that intra-individual variation in circulating polyphenol levels were unaccounted for, which could have caused attenuation of the observed risk estimates.

In conclusion, in this prospective analysis which measured circulating concentrations of 35 polyphenols, levels of equol were inversely, and those of homovanillic acid positively, associated with colon cancer development. Further studies of the relationships between equol and homovanillic acid and colon cancer are now warranted, but these novel findings suggest that circulating levels of these polyphenols may be indicative of direct effects of polyphenols on colon cancer development or could represent specific pathways or phenotypes that are relevant for colon tumorigenesis.

References

1. Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727-47.

2. Pérez-Jiménez J, Neveu V, Vos F, et al. Systematic analysis of the content of 502 polyphenols in 452 foods and beverages: an application of the phenol-explorer database. J Agric Food Chem 2010;58:4959-69. [published Online First: 2010/03/23]

3. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr 2005;81:2155-2175.

4. Gonzalez R, Ballester I, Lopez-Posadas R, et al. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr 2011;51:31-62. [published Online First: 2011/03/25]

5. Barnes S. Soy isoflavones—phytoestrogens and bioavailability. Am J Clin Nutr 2004;79:581-586.

6. Rothwell JA, Urpi-Sarda M, Boto-Ordonez M, et al. Systematic analysis of the polyphenol metabolome using the Phenol-Explorer database. Mol Nutr Food Res 2016;60:203-11.

7. Janicke B, Hegardt C, Krogh M, et al. The anti-proliferative effect of dietary fiber phenolic compounds feralic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr Cancer 2011;63:611-22. [published Online First: 2011/04/19]

8. Kang NJ, Lee KW, Shin BJ, et al. Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression. Carcinogenesis 2008;30:321-30.

9. Kang NJ, Lee KW, Kim BH, et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. Carcinogenesis 2011;32:921-8. [published Online First: 2011/02/15]

10. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006;20:187-210. [published Online First: 2005/11/18]

11. Pan MH, Lai CS, Wu JC, et al. Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol Nutr Food Res 2011;55:32-45. [published Online First: 2011/01/06]

12. Matsunaga K, Katayama M, Sakata K, et al. Inhibitory effects of chlorogenic acid on azoxymethane-induced colon carcinogenesis in male F344 rats. Asian Pac J Cancer Prev 2002;5:109-113. [published Online First: 2003/04/30]

13. Lin J, Zhang SM, Wu K, et al. Flavonoid intake and colorectal cancer risk in men and women. Am J Epidemiol 2006;164:444-51. [published Online First: 2006/08/23]

14. Nimptsch K, Zhang X, Cassidy A, et al. Habitual intake of flavonoid subclasses and risk of colorectal cancer in 2 large prospective cohorts. Am J Clin Nutr 2016;103:184-91. [published Online First: 2015/11/06 06:00]

15. Zamora-Ros R, Barupal DK, Rothwell JA, et al. Dietary flavonoid intake and colorectal cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort. Int J Cancer 2017;140:1836-44.

16. Ward H, Chapelas G, Kuhne GGC, et al. Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk Study. Cancer Epidemiol Bio Mark Prev 2008;17:2891-4.

17. Zamora-Ros R, Touillaud M, Rothwell JA, et al. Measuring exposure to the polyphenol metabolome in observational epidemiologic studies: current tools and applications and their limitations. Am J Clin Nutr 2014;100:11-26.

18. Yuan J-M, Gao Y-T, Yang CS, et al. Urinary biomarkers of tea polyphenols and risk of colorectal cancer in the Shanghai Cohort Study. Int J Cancer 2007;120:1344-50.

19. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Int. J. Cancer: 143, 1620–1631 (2018) © 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
metabolite produced by human intestinal bacteria. 21. Kuhnle GG, Dell’aquila C, Aspinall SM, et al. Phytoestrogen content of foods of animal origin: dairy products, eggs, meat, fish, and seafood. J Agric Food Chem 2008;56:10099–104 [published Online First: 2008/10/17].
22. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr 2010;140:1355s–1362s. [published Online First: 2010/06/04]
23. Zamora-Ros R, Achaintre D, Rothwell JA, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113–24.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995;57:289–300.
25. Kurohashi N, Iwasaki M, Inoue M, et al. Isolated isoflavones do not affect the circulatory profile and characterisation of an equol-producing metabolite produced by human intestinal bacteria. Int J Epidemiol 1997;26:145–52.
26. Kurashiki N, Iwasaki M, Inoue M, et al. Plasma isoflavones and subsequent risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition–Norfolk in relation to phytoestrogen intake derived from an improved database. Am J Clin Nutr 2010;91:440–8.
27. Ward HA, Kuhnle GG, Mugilan AA, et al. Urinary excretions of 34 dietary polyphenols and their associations with lifestyle factors in the EPIC cohort study. Sci Rep 2016;6:26905.
28. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone isoflavone daidzin to equol. Metabolomics 2015;13:56–73. [published Online First: 2015/01/17].
29. Hartman J, Edvardsson K, Lindberg K, et al. Tumor suppressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009; 69:6100–6.
30. Woliszewski P, Blasczyk M, Wolinska-Wittor E, et al. Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas. J Surg Oncol 1997;64:3–11.
31. Castiglione F, Taddei A, Rossi Degl’Innocenti D, et al. Expression of estrogen receptor beta in colon cancer progression. Diag Mol Pathol 2008; 17:231–6. [published Online First: 2008/11/27]
32. Nanda KF, Bastian LAFAU, Hasselbalb VF, et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93(5 Pt 2):880–88.
33. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574–82.
34. Green J, Cranner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case–control study within a prospective cohort, and meta-analysis. Int J Cancer 2012; 130:2387–96.
35. Murphy N, Strickler HD, Stanczyk FZ, et al. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. JNCI J Natl Cancer Inst 2015;107:djv210.
36. Lampe JW. Emerging research on equol and cancer. Am J Clin Nutr 2005;81:1072–9. [published Online First: 2005/05/11]
37. Hartman J, Edvardsson K, Lindberg K, et al. Tumor suppressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009; 69:6100–6.
38. Decroos K, Vanhemmens S, Cattoir S, et al. Isolation and characterization of an equol-producing microbial culture from a human faecal sample and its activity under gastrointestinal conditions. Arch Microbiol 2005;183:45–55. [published Online First: 2004/12/04]
39. Rafii F. The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equol. Metabolomics 2015;13:56–73. [published Online First: 2015/01/17].
40. Vrielink A, Rookus MA, Kampman E, et al. Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk. J Nutr 2007;137:379–83. [published Online First: 2007/01/24]
41. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010; 126:1702NA–15.
42. Goldstein DS, Eisenhofer G, Kopin I. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003;305:800–11. [published Online First: 2003/03/22]
43. Gemignani F, Landi S, Moreno V, et al. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiol Biomark Prev 2005;14:1633–8.
44. Sarkar C, Chakroborty D, Chowdhury UR, et al. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008;14:2502–10.
45. Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004;4:206–15.
46. Scalbert A, Rothwell JA, Keski-Rahkonen P, et al. The food metabolome and dietary biomarkers In: Schoeller D, Westerterp-Plantenga M, eds. Advances in the assessment of dietary intake. Boca Raton: CRC Press, 2017. 259–282.